Alpha Teknova, Inc. TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2021 · data as of November 13, 2026
Alpha Teknova, Inc. (TKNO) is a healthcare company listed in the US with a market value of about $516M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$16M, a net margin of -34.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of -21%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About Alpha Teknova
Alpha Teknova is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2021. Revenue went from $31M in 2020 to $41M in 2025, growth of about 5.3% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 90% over three years (dilution for shareholders). It spends 5% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $46M | $41M | $38M | $37M | $41M | $37M | $31M |
| Net income | -$16M | -$17M | -$27M | -$37M | -$47M | -$10M | $4M |
| Free cash flow | -$6M | -$10M | -$14M | -$27M | -$56M | -$29M | -$3M |
| EPS (diluted) | $-0.29 | $-0.32 | $-0.57 | $-1.16 | $-1.69 | $-0.61 | $0.16 |
| Net margin | -34.8% | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% | 11.4% |
| ROIC | — | -13.8% | -24.0% | -29.3% | -33.6% | -5.3% | 21.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $9.83, 20% above the current price; targets range from $8.00 to $12.00; the consensus rating is “Strong buy”; expected EPS is $-0.23 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Alpha Teknova stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alpha Teknova pay a dividend?
Not currently.
Is Alpha Teknova a good stock to buy?
We do not give buy or sell advice. Alpha Teknova scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.